Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January

Citius Oncology, Inc. (NASDAQ:CTOR) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,202,807 shares, an increase of 22.3% from the December 31st total of 983,877 shares. Based on an average daily trading volume, of 285,256 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.5% of the shares of the company are sold short. Currently, 1.5% of the shares of the company are sold short. Based on an average daily trading volume, of 285,256 shares, the days-to-cover ratio is currently 4.2 days.

Hedge Funds Weigh In On Citius Oncology

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE lifted its position in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after buying an additional 8,411 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of Citius Oncology during the 2nd quarter worth about $51,000. Citadel Advisors LLC acquired a new stake in shares of Citius Oncology during the 3rd quarter valued at about $36,000. IFP Advisors Inc grew its stake in shares of Citius Oncology by 49.5% in the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after buying an additional 11,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after buying an additional 36,758 shares during the last quarter. Institutional investors and hedge funds own 70.52% of the company’s stock.

Citius Oncology Trading Up 2.8%

Shares of NASDAQ CTOR traded up $0.03 during midday trading on Tuesday, reaching $1.11. 46,571 shares of the company traded hands, compared to its average volume of 209,700. The stock has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.54. Citius Oncology has a 52 week low of $0.55 and a 52 week high of $6.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.56 and a quick ratio of 0.11.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06).

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.